bortezomib + cytarabine + dexamethasone

This refers to a combination therapy regimen consisting of bortezomib, cytarabine, and dexamethasone, which was evaluated in a Phase 2 clinical trial (NCT01793584) led by Seoul National University Hospital for the treatment of relapsed or refractory mantle cell lymphoma (MCL). The regimen combines the proteasome-inhibiting activity of bortezomib, which induces cell cycle arrest and apoptosis, with the antimetabolite effects of cytarabine, which inhibits DNA synthesis. Dexamethasone, a potent synthetic glucocorticoid, is included for its lympholytic properties and its ability to enhance the efficacy of the other agents. The trial specifically targeted patients who had failed 1 to 3 prior lines of therapy and utilized pegteograstim (or pegfilgrastim) for myeloid support to manage hematologic toxicity. Results from this study were published in the British Journal of Haematology in 2023.

Other names

BCD regimenBortezomib-Cytarabine-Dexamethasone